EU OKs Novartis’ gene therapy Luxturna for rare retinal disease

25th November 2018 Uncategorised 0

Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.

More: EU OKs Novartis’ gene therapy Luxturna for rare retinal disease
Source: News